Eli Lilly and Company (NYSE:LLY) Stake Raised by Navellier & Associates Inc.

Navellier & Associates Inc. grew its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 71.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,852 shares of the company’s stock after acquiring an additional 9,125 shares during the quarter. Eli Lilly and Company comprises approximately 2.0% of Navellier & Associates Inc.’s investment portfolio, making the stock its 6th biggest position. Navellier & Associates Inc.’s holdings in Eli Lilly and Company were worth $11,737,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $27,000. Retirement Group LLC increased its position in shares of Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares during the last quarter. Cornerstone Planning Group LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth about $33,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $35,000. Finally, Family CFO Inc acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $40,000. 81.38% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders have sold 195,055 shares of company stock valued at $125,254,657. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Citigroup lifted their target price on Eli Lilly and Company from $525.00 to $675.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Morgan Stanley lifted their target price on Eli Lilly and Company from $763.00 to $805.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Deutsche Bank Aktiengesellschaft assumed coverage on Eli Lilly and Company in a research report on Thursday, November 9th. They issued a “hold” rating and a $535.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $630.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 1st. Finally, UBS Group reaffirmed a “buy” rating and issued a $710.00 target price (up from $612.00) on shares of Eli Lilly and Company in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $621.81.

View Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Stock Down 1.0 %

LLY stock traded down $7.41 during trading on Monday, hitting $732.75. 1,250,868 shares of the company’s stock were exchanged, compared to its average volume of 3,367,006. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59. Eli Lilly and Company has a 52-week low of $309.20 and a 52-week high of $745.70. The business has a 50-day moving average price of $620.02 and a two-hundred day moving average price of $581.92. The stock has a market capitalization of $695.61 billion, a price-to-earnings ratio of 127.61, a PEG ratio of 2.08 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a return on equity of 50.78% and a net margin of 15.36%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.09 earnings per share. As a group, equities research analysts expect that Eli Lilly and Company will post 12.52 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Stockholders of record on Thursday, February 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.71%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s payout ratio is presently 77.93%.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Recommended Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.